RxDoctor Payments Data

Nicolas Karam, MD

Clinical Cardiac Electrophysiology · Plattsburgh, NYNPI 1760527113

Payments from drug & device makers

$27,377in general payments, 2019–2025

Across 303 payments — averaging $90.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$27K
  • Abbott$134
  • Novartis$30
  • Scpharmaceuticals Inc.$19
  • Johnson & Johnson$11

What the payments were for

  • Travel & lodging$12,61846%
  • Food & beverage$14,75954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)295$27,183
Abbott4$134
Novartis2$30
Scpharmaceuticals Inc.1$19
Johnson & Johnson1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,377 in reported general payments places this provider in the 45th percentile of 214 clinical cardiac electrophysiology providers in New York.

See all clinical cardiac electrophysiology providers in New York

Medicare billing

Part B allowed, 2024
$219,250
Medicare patients
1,547
Services billed
4,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban309$419,576
EntrestoSacubitril/Valsartan94$137,971
JardianceEmpagliflozin53$61,683
Dofetilide89$31,105
XareltoRivaroxaban19$30,091
Bisoprolol Fumarate133$4,021
Metoprolol Succinate116$1,847
SotalolSotalol Hcl56$1,425
Amiodarone Hcl100$1,348
Potassium Chloride36$1,077
Flecainide Acetate23$963
Verapamil SrVerapamil Hcl11$838
Rosuvastatin Calcium43$673
Losartan Potassium79$649
Nebivolol Hcl14$647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$30$137,97194 claims
Johnson & JohnsonXarelto$11$30,09119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 214 clinical cardiac electrophysiology providers in New York.

Other clinical cardiac electrophysiology in Plattsburgh

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →